Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric S Daar

Showing results (181-190 of 222) with videos related to

Pageof 23
Sort By:
Biorxiv : the Preprint Server for Biology|November 14, 2023
Early antiviral CD4 and CD8 T cell responses and antibodies are associated with upper respiratory tract clearance of SARS-CoV-2Sydney I Ramirez, Paul G Lopez, Farhoud Faraji, et al.
Iscience|March 24, 2025
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodiesRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
The Journal of Infectious Diseases|July 22, 2024
SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody FeedbackNathaniel Bloom, Sydney I Ramirez, Hallie Cohn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 6, 2023
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 TrialNikolaus Jilg, Kara W Chew, Mark J Giganti, et al.
Journal of Virology|June 27, 2014
Impaired Nef function is associated with early control of HIV-1 viremiaXiaomei T Kuang, Xiaoguang Li, Gursev Anmole, et al.
Journal of Clinical and Translational Science|October 31, 2024
ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemicMaryam Keshtkar-Jahromi, Kevin J Anstrom, Christina Barkauskas, et al.
Journal of Clinical and Translational Science|November 14, 2024
ACTIV trials: cross-trial lessons learned for master protocol implementationMaryam Keshtkar-Jahromi, Stacey J Adam, Indira Brar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 17, 2025
Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled TrialAnne F Luetkemeyer, Kara W Chew, Stuart Lacey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 15, 2023
Antiretroviral Therapy Intensification for Neurocognitive Impairment in Human Immunodeficiency VirusScott L Letendre, Huichao Chen, Ashley McKhann, et al.
Medrxiv : the Preprint Server for Health Sciences|January 4, 2022
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical TrialKara W Chew, Carlee Moser, Eric S Daar, et al.
Pageof 23

Showing results (181-190 of 222) with videos related to

Sort By:
Pageof 23
Biorxiv : the Preprint Server for Biology|November 14, 2023
Early antiviral CD4 and CD8 T cell responses and antibodies are associated with upper respiratory tract clearance of SARS-CoV-2Sydney I Ramirez, Paul G Lopez, Farhoud Faraji, et al.
Iscience|March 24, 2025
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodiesRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
The Journal of Infectious Diseases|July 22, 2024
SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody FeedbackNathaniel Bloom, Sydney I Ramirez, Hallie Cohn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 6, 2023
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 TrialNikolaus Jilg, Kara W Chew, Mark J Giganti, et al.
Journal of Virology|June 27, 2014
Impaired Nef function is associated with early control of HIV-1 viremiaXiaomei T Kuang, Xiaoguang Li, Gursev Anmole, et al.
Journal of Clinical and Translational Science|October 31, 2024
ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemicMaryam Keshtkar-Jahromi, Kevin J Anstrom, Christina Barkauskas, et al.
Journal of Clinical and Translational Science|November 14, 2024
ACTIV trials: cross-trial lessons learned for master protocol implementationMaryam Keshtkar-Jahromi, Stacey J Adam, Indira Brar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 17, 2025
Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled TrialAnne F Luetkemeyer, Kara W Chew, Stuart Lacey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 15, 2023
Antiretroviral Therapy Intensification for Neurocognitive Impairment in Human Immunodeficiency VirusScott L Letendre, Huichao Chen, Ashley McKhann, et al.
Medrxiv : the Preprint Server for Health Sciences|January 4, 2022
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical TrialKara W Chew, Carlee Moser, Eric S Daar, et al.
Pageof 23